INTRODUCTION

Focal cortical dysplasia (FCD) is a heterogeneous group of disorders, which can be the cause of drug-resistant epilepsy or intractable epilepsy. In medical practice, “dysplasia” is used as variable meanings, as pre-neoplastic (e.g., epithelial dysplasia of stomach), developmental anomaly (e.g., renal dysplasia) or etc. Originally “dysplasia” was a term used to refer an abnormality of development, alternation in size, shape and organization of adult cells. Blümcke et al. defined this terminology as “any tissue that is imperfectly developed in embryonic or fetal life. However, dysplasia is a diagnostic term used here to identify specific malformations of the cortex, the so-called FCDs, irrespective of their diverse histologic appearances that are addressed by this classification” in their paper. Therefore, it is obvious that FCDs have a meaning of developmental abnormalities including cortical dyslamination, cytarchitectural lesions, and underlying abnormalities of white matter.

THE SHORT HISTORY OF FCD

In 1971, Taylor et al. reported the 10 patients with drug-resistant epilepsy and described several histological findings, cortical disorganization, large bizarre neurons and balloon...
cells which are characteristic findings of the current classification of FCDs. In this paper, they described these features as “Focal dysplasias of cerebral cortex”. Previously, Crome had described three cases of intractable epilepsy. He described “dysmorphic neurons” as “giant nerve cells” in his cases.

After that, many researchers used different terminologies in discussing FCDs. Although the etiology is exactly unknown, it is accepted that many lesions are related to the alteration of cortical development caused by a variety of mechanisms. In 1992, Meencke and Veith introduced “microdysgenesis” as a minor parenchymal malformation in patients with generalized epilepsy. They described many characteristic histological findings from their cases. These findings were largely overlapped with the features in current classification system of FCD. In 1996, the terminology of “malformation of cortical development (MCD)” was introduced to designate collectively a common group of disorders in children with developmental delay and young people with epilepsy. They categorized these disorders as group I, II, and III. FCD was categorized as group III-B. In the past, MCDs have been defined as “neuronal migration disorder”; however, as not all the cortical abnormalities have been proven to be due to migrational derangements, the general term of MCDs was preferred.

In 2004, Palmini et al. suggested FCD classification. After panel discussion, they proposed as follows: 1) a specific terminology for the different types of abnormal cells encountered in the cerebral cortex of patients with FCD; 2) a reappraisal of the different histopathologic abnormalities usually subsumed under the term “microdysgenesis,” and suggested that this terminology be abandoned; and 3) a more detailed yet straightforward classification of the various histopathologic features that usually are included under the heterogeneous term of “focal cortical dysplasia.”

Therefore, they classified the lesions as mild MCD (mild MCD) and FCD. In addition, they classified each entity into type I and II respectively (Table 1).

With advances in clinical, histological, radiological and genetic understanding of FCDs, International League Against Epilepsy (ILAE) Task Force proposed a three-tiered classification system in 2011.

### Table 1. Classification of cortical dysplasias in epilepsy

<table>
<thead>
<tr>
<th>Focal dysplasia type</th>
<th>Subtype</th>
<th>Main neuropathological features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild MCD</td>
<td>Type I</td>
<td>Heterotopic/excess neurons in layer I</td>
</tr>
<tr>
<td></td>
<td>Type II</td>
<td>Heterotopic/excess neurons outside in layer I</td>
</tr>
<tr>
<td>FCD type I</td>
<td>Type Ia</td>
<td>Cortical dyslamination only (±MCD features)</td>
</tr>
<tr>
<td></td>
<td>Type Ib</td>
<td>Cortical dyslamination + giant* or immature neurons†</td>
</tr>
<tr>
<td>FCD type II (Taylor-type)</td>
<td>Type IIa</td>
<td>Cortical dyslamination + dysmorphic neurons‡</td>
</tr>
<tr>
<td></td>
<td>Type IIb</td>
<td>Cortical dyslamination + dysmorphic neurons and balloon cells</td>
</tr>
</tbody>
</table>

In Palmini’s classification, ‘giant neurons’ were described focusing on cell size. In the other hand, ‘dysmorphic neurons’ were described focusing on abnormal morphology and aggregated coarse Nissl substance. The abnormal neurons in Figs. 5B are similar to the ‘giant neurons’ and cells in Fig. 6B are similar to the ‘dysmorphic neurons’ in Palmini et al.’s classification. In the current classification, the definition of dysmorphic neuron has two morphologic features, both large size and characteristic Nissl substance. According to Palmini et al.’s classification, giant neurons are neurons of increased size (compared with layer V pyramidal neurons) with central nuclei. The immature neurons are round cells with immature nucleus, not dysmorphic or giant. They could be seen in heterotopic nodules. Dysmorphic neurons are cells with abnormal orientation, size, cytoskeletal structures and atypical dendritic processes. Nissl substance can be seen in clumps. MCD: malformation of cortical development, FCD: focal cortical dysplasia.
later phases of cortical development might show the distinctive histopathology, such as cortical dysplasia. And local interactions of dysmature cells with normal postnatal neurons might promote seizures. Especially the basic concept of FCD type I was established from the Hildebrandt et al.'s morphometric study.8

On contrary to Palmini et al.'s system, the ILAE classification system of FCD has a three-tier system. This system composed of isolated FCDs (FCD type I and II) and variants associated with other (potentially) epileptogenic lesions (FCD type III). The definition of FCD type III was cortical dyslaminolation abnormalities associated with a principal lesion, usually adjacent to or affecting the same cortical area/lobe. The basic concept of type III seems to base on that there were some disturbances of normal cortical six layers adjacent the main lesion. In addition, it might be very difficult to identify these “subtle” cortical abnormalities from the histologic changes of “secondary reactive process, resulting from the main lesions.

Meanwhile, the mild MCD (mMCD) was not included the current system. Therefore, the mMCDs in Blümcke et al.'s paper were classified according to the Palmini et al.'s classification.11

To get the best possible histologic assessment and reduce sampling errors, the standardized procedures for inspection, distribution and processing of epileptogenic brain tissue are very important. Especially, the surgical procedures, resulting on piecemeal fragmentations of tissue should be avoided for pathologic diagnosis. The Task Force of ILAE commission on Diagnostic Methods suggested the International recommendation for a comprehensive neuropathologic workup of epilepsy surgery brain tissue. They emphasized an en-bloc resection, anatomical oriented landmarks and 5 mm serial cutting, perpendicular to the pia. The immunohistochemical staining had become a routine procedure for the diagnosis. For example, the neuronal markers (e.g., NeuN) are essential to diagnosis certain type of FCD, especially in type I.

They defined the words, “dual pathology” and “double pathology”. They proposed the “dual pathology” as only in hippocampal sclerosis (HS), a second principal lesion affecting the brain, that is, tumor, vascular malformation, glial scar, limbic/Rasmussen encephalitis, or MCD (including FCD type IIa/IIb). If there is an architectural abnormality in the temporal lobe in HS patients, we should diagnosis as FCD type IIIa, instead of FCD type I or dual pathology. The double pathology meant that two independent lesions affecting one or multiple lobe, without HS. It meant that both lesions might originate from independent pathogenesis. For example; cavernous angioina in right temporal lobe and ganglioglioma in left temporal lobe.

In summary, 1) If HS plus FCD type I features in the temporal lobe is FCD type IIIa. 2) If HS plus other lesion (FCD type II, tumor, scar, or encephalitis) is a dual pathology. And 3) lesion A

---

**Fig. 1.** The low power view of normal neocortex (NeuN, ×40) and a Korean folding pan (inlet). The imaginary white lines show the direction of radial migrations of neural cells. The lines look like the bones of a folding pan (inlet). The cortical six-layers were seen with red imaginary lines. The red imaginary lines show the tangential composition of neocortex. In the normal neocortex, it is unusual that the neuronal cells exactly align along the white imaginary lines.

**Fig. 2.** The low power view of the neocortex in FCD type Ia (NeuN, ×40). In contrast to the normal neocortex, many neuronal cells in FCD type Ia show linear alignment as shown in the dot-line box. FCD : focal cortical dysplasia.
(except HS) plus lesion B (except HS) is a double pathology.

The clinico-radiologic-pathological correlation is very essential in diagnosis. For example, the histological features of hemimegalencephaly, tuberous sclerosis or schizencephaly could be overlapped with FCD type II. Comprehensive review of patient clinical information would provide a diagnos-

**Fig. 3.** In high power view of the box (NeuN, ×200), the so-called many microcolumns, which were defined more than eight neurons aligned in a vertical direction, are noted (red boxes).

**Fig. 4.** The low power view of FCD type Ib (NeuN, ×40). The cortical six-layers are deranged (too chaotic) compared to those in normal neocortex (Fig. 1). FCD: focal cortical dysplasia.

**Fig. 5.** The histopathological findings of FCD type IIa. The low power view (A; H-E, ×40) shows cortical dyslamination which means derangement of normal neocortical six-layers. High power view shows many large dysmorphic neurons with coarse Nissl substances. The size of dysmorphic neuron cytoplasm is more than 20 µm (B; H-E, ×400; black bar, 20 µm). Dysmorphic neurons are highlighted by immunostaining with nonphosphorylated neurofilament (C; SMI132, ×200). FCD: focal cortical dysplasia.

**Fig. 6.** The histopathological findings of FCD type IIb. The low power view (A; H-E, ×40) shows cortical dyslamination as FCD type IIa. High power view shows many large dysmorphic neurons with coarse Nissl substances (B; H-E, ×400; black bar, 20 µm) and balloon cells showing eosinophilic homogenous cytoplasm (C; H-E, ×400; black bar, 20 µm). FCD: focal cortical dysplasia.
tic clue.

**FCD type I**

FCD Type I is a malformation characterized by abnormal cortical layering, which is caused by abnormal process in either radial migration of neurons (FCD type Ia) or the six-layered tangential composition of the neocortex (FCD type Ib). The combination of both conditions will be classified as FCD type Ic. Before the understanding of the pathology of FCD type Ia, we have to remind what are “radial” and “tangential” (Fig. 1). Because the neuronal progenitor cells migrate along the radial glial cells, the radial migration looks like the bones of “a folding pan (Fig. 1, inlet)” in the microscopic examination (Fig. 1, white lines). And it is important to understand the definition of “microcolumn”⁵. The definition of “microcolumn” is more than eight neurons aligned in a vertical direction (Figs. 2 and 3). The concept of microcolumn was firstly introduced in Hildebrandt et al.’s paper⁸. On their observation, the cells of microcolumn had smaller perikarya. During the developmental period, primitive neuronal cells start to differentiate to several types and sizes after 22-weeks of gestation and the microcolumns begin to disappear. The pattern of microcolumn is unusual histological findings in postnatal controls (Fig. 1), except for occipital area. These findings suggested that the cortical maturation arrest may cause FCD type Ia.

The tangential compositions of the neocortex are completed.

**Table 2. The current three-tired ILAE classification system of FCD⁵**

<table>
<thead>
<tr>
<th>FCD type I (isolated)</th>
<th>Focal cortical dysplasia with abnormal radial cortical lamination (FCD type Ia)</th>
<th>Focal cortical dysplasia with abnormal tangential cortical lamination (FCD type Ib)</th>
<th>Focal cortical dysplasia with abnormal radial and tangential cortical lamination (FCD type Ic)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FCD type II (isolated)</td>
<td>Focal cortical dysplasia with dysmorphic neurons (FCD type IIa)</td>
<td>Focal cortical dysplasia with dysmorphic neurons and balloon cells (FCD type IIb)</td>
<td></td>
</tr>
<tr>
<td>FCD type III (associated with principal lesion)</td>
<td>Cortical lamination abnormalities in the temporal lobe associated with hippocampal sclerosis (FCD type IIIa)</td>
<td>Cortical lamination abnormalities adjacent to a glial or glioneuronal tumor (FCD type IIIb)</td>
<td>Cortical lamination abnormalities adjacent to vascular malformation (FCD type IIIc)</td>
</tr>
</tbody>
</table>

FCD type III (NOS): if clinically/radiologically suspected principal lesion is not available for microscopic inspection. Please note that the rare association between FCD type IIa and IIb with hippocampal sclerosis, tumors, or vascular malformations should not be classified as FCD type III variant. ILAE: international league against epilepsy, FCD: focal cortical dysplasia, NOS: not otherwise specified.

**Fig. 7.** FCD type IIIa is a hippocampal sclerosis (ILAE type Ia) showing neuronal loss in CA4, 3, 2 and 1 (A; NeuN, ×12) with associating FCD type Ib which shows a breakdown of cortical tangential composition in overlying cortex (B; NeuN, ×40). FCD: focal cortical dysplasia.
after the radial migration. The tangential composition looks like “concentric lamella” (Fig. 1, red lines). Usually The FCD type Ib shows the derangements of cortical six-layers (Fig. 4).

The FCD type Ic is the combination of both variants. Even the neuropathologic experts doubts whether it is real entity or not.

**FCD type II**

These are undoubtedly definite categories. Also in Palmini et al.’s classification, these entities were almost the same. The hallmark of these FCD variants were presence of cortical dyslamination and dysmorphic neurons without (FCD type IIa) (Fig. 5) or with balloon cells (FCD type IIb) (Fig. 6). In the ILAE classification of FCD, the detailed morphological defi-

---

**Table 3. Suggestions for an update to the ILAE classification of FCD**

<table>
<thead>
<tr>
<th>FCD type I (isolated)</th>
<th>Histology</th>
<th>Update needed</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>FCD type Ia</td>
<td>Abnormal radial cortical lamination</td>
<td>Yes</td>
<td>Molecular biomarkers needed to confirm specific pathomechanism</td>
</tr>
<tr>
<td>FCD type Ib</td>
<td>Abnormal tangential cortical lamination</td>
<td>Yes</td>
<td>Molecular biomarkers needed to confirm specific pathomechanism</td>
</tr>
<tr>
<td>FCD type Ic</td>
<td>Abnormal radial and tangential cortical lamination</td>
<td>No</td>
<td>Molecular biomarkers needed to confirm specific pathomechanism</td>
</tr>
</tbody>
</table>

**FCD type II (isolated)**

| FCD type IIa          | Dysmorphic neurons                          | Yes           | Introduce genetic findings of mTOR activation       |
| FCD type IIb          | Dysmorphic neurons and balloon cells        | Yes           | Introduce genetic findings of mTOR activation and new variant at bottom-of-sulcus |

**FCD type III (associated)**

| FCD type IIIa         | Cortical lamination abnormalities in the temporal lobe associated with hippocampal sclerosis | No            | Molecular and clinical biomarkers needed to differentiate between secondary (acquired) or primary etiology |
| FCD type IIIb         | Cortical lamination abnormalities adjacent to a glial or glioneuronal tumor          | No            | Molecular and clinical biomarkers needed to differentiate between secondary (acquired) or primary etiology |
| FCD type IIIc         | Cortical lamination abnormalities adjacent to vascular malformation                | No            | Molecular and clinical biomarkers needed to differentiate between secondary (acquired) or primary etiology |
| FCD type IIId         | Cortical lamination abnormalities adjacent to any other lesion acquired during early life | Yes           | Molecular and clinical biomarkers needed to differentiate between secondary (acquired) or primary etiology; introduce FCD type IIId with loss of layer four neurons in occipital lobe |

---

*ILAE*: international league against epilepsy, *FCD*: focal cortical dysplasia, *mTOR*: mammalian target of rapamycin
nitions of dysmorphic neurons (cell size 16–43 µm, nucleus
diameter 15–28 µm, the characteristic Nissl substance and
immunohistochemical stainings) were emphasized. More-
over, the morphological and immunohistochemical features
of balloon cells were detailed.

**FCD type III**

The FCD type III is classified into four subcategories (Table 2)
based on histological features of principal lesion. If histologi-
cal examination is not available, it is recommended to use Not
Otherwise Specified (NOS). The concept of FCD type III can
be simply defined as FCD type I adjacent to another principal
lesion. For understanding of this concept, it is better to men-
tion “Temporal lobe sclerosis” by Thom et al. reported ap-
proximately 10% of HS cases showed a horizontal cortical
dyslamination with neuronal loss in temporal neocortex. Re-

calling their frequent association, co-existence of HS and
FCD type I are classified as FCD IIIa (Fig. 7), but not as con-
current type I and type III. Similarly, FCD type I associated
with other lesions (such as tumor, vascular lesion, and etc.)
were classified as FCD type IIIb (Fig. 8), IIIc, and IIId, respec-
tively.

It is not well known about the pathogenesis of FCD type III.
As noted above, it is very difficult to differentiate whether the
cortical dyslamination was primary or secondary.

**Limitations, genetic progress and prospect**

In our opinion, major limitation of this system is low inter-
observer agreement, especially, occurring in the assessment of
type I and III. In addition, the definition of mMCD was still
not clearly established. Nowadays, a lot of research papers re-
garding genetic information in FCD are published. Detailed
review of the updates in genetics of FCD is beyond the pur-
pose of this paper. Briefly, recent genomic data suggests that
alteration of mammalian target of rapamycin (mTOR) path-
way and mutations of Tuberous sclerosis (TSC) gene play an
important role in pathogenesis of FCD. With the advanced
knowledge in genetics, it is needed to update the current clas-
sification. The concept of integrated diagnosis upon clinical-
pathological and molecular findings has been recently sug-
gested (Table 3). The authors carefully expect that the next
classification system of FCD might be similar to the current
World Health Organization (WHO) central nervous system
(CNS) tumor classification.

There is no “perfect” disease classification system. Accord-
ing to technical progressions and disease paradigm changes, it
should be updated. This virtuous cycle will be essential to
make better disease classification. This effort will provide a
better medical care for patient with epilepsy.

**CONFLICTS OF INTEREST**

No potential conflict of interest relevant to this article was
reported.

**INFORMED CONSENT**

This type of study does not require informed consent.

- Acknowledgements

This work was supported by the Brain Research Program
through the National Research Foundation of Korea (NRF),
funded by the Ministry of Science, ICT & Future Planning
(2016M3C7A1913844), NRF-2017R1D1AB03033362 and NRF-2018R1A6A1A03023718.

The authors express their gratitude to their good mentors,
Dr. Blümcke, I. (Erlangen, Germany), Dr. Sarnat, H.B. (Cal-
gary, Canada), and Dr. Aronica, E. (Amsterdam, Netherlands)
for their excellent inspirations and advices over the years.

**References**

1. Aronica E, Becker AJ, Sprefacio R: Malformations of cortical develop-
2. Barkovich AJ, Guerrini R, Kuzniecky RI, Jackson GD, Dobyns WB: A
developmental and genetic classification for malformations of cortical
workup of epilepsy surgery brain tissue: a consensus task force report from the ILAE commission on diagnostic methods. *Epilepsia* 57: 348-
358, 2016
5. Blümcke I, Thom M, Aronica E, Armstrong DD, Vinters HV, Palmini A,